Smiths Medical Acquires Zhejiang Zheda Medical Instrument
This article was originally published in PharmAsia News
Executive Summary
Smiths Medical, part of Smiths Group plc, has acquired Zhejiang Zheda Medical Instrument, which enjoys China's largest market share of medical infusion pumps. The move shows Smiths Medical's continued confidence and commitment in the country following the establishment of its China headquarters last year. With independent intellectual property rights and patents for medical infusion pumps, Zhejiang Zheda passed TUV Rhine's CE certificate in 2005. It subsequently entered the European market and its export growth rate exceeded 200 percent in the following two years. Besides maintaining Zhejiang Zheda's existing products and services, Smiths Medical says it will develop more products to cater to the requirements of global and local markets. (Click here for more - Chinese Language)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.